ANIX
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 8.08 · operating margin 0.0%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 67 036 titres (~181 206,84 $ US)
- Insiders
- Titterton Lewis H jrKUMAR AMIT
- Total bought
-
$181,207
Avg buy (VWAP, 90d window) $3.21 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-23
- Last synced
-
2026-09-25 21:09:17
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | Titterton Lewis H jr | Buy | 10,000 | $2.73 | $27,300 | Form 4 |
| 2026-09-10 | KUMAR AMIT | Buy | 5,000 | $2.76 | $13,800 | Form 4 |
| 2026-07-31 | KUMAR AMIT | Buy | 5,000 | $3.47 | $17,350 | Form 4 |
| 2026-07-27 | KUMAR AMIT | Buy | 3,188 | $3.37 | $10,744 | Form 4 |
| 2026-07-24 | KUMAR AMIT | Buy | 3,000 | $3.73 | $11,190 | Form 4 |
| 2026-07-20 | KUMAR AMIT | Buy | 5,000 | $3.46 | $17,300 | Form 4 |
| 2026-07-20 | Titterton Lewis H jr | Buy | 12,000 | $3.47 | $41,640 | Form 4 |
| 2026-07-15 | Titterton Lewis H jr | Buy | 2,797 | $3.28 | $9,174 | Form 4 |
| 2026-07-10 | KUMAR AMIT | Buy | 5,000 | $3.04 | $15,200 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-04
ANIX presents a genuine event-driven catalyst — insider cluster buys, a Zacks Strong Buy upgrade, international patent acceptances, and positive Phase 1/CAR-T clinical data — that warrants attention from a speculative…
The first sentence of the analysis written for ANIX on 2026-08-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 23.3% | 0.0% | 24.8% | |
| Ebit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2565.6% | |
| Ebitda Margin | 0.0% | 0.0% | -4706.7% | 0.0% | -2554.9% | |
| Operating Profit Margin | 0.0% | 0.0% | -5243.3% | 0.0% | -2565.6% | |
| Pretax Profit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2564.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2564.0% | |
| Net Profit Margin | 0.0% | 0.0% | -4671.9% | 0.0% | -2528.6% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -4671.9% | 0.0% | -2530.1% | |
| Current Ratio | 8.077 | 8.545 | 12.503 | 14.826 | 28.349 | |
| Quick Ratio | 8.077 | 8.545 | 12.503 | 14.848 | 28.349 | |
| Solvency Ratio | -5.113 | -4.631 | -4.540 | -6.127 | -8.645 | |
| Cash Ratio | 0.632 | 0.508 | 0.451 | 6.068 | 22.936 | |
| Price To Earnings Ratio | -12.147 | -8.974 | -9.875 | -12.444 | -11.311 | |
| Price To Earnings Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Forward Price To Earnings Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Price To Earnings Diluted Ratio | -12.147 | -8.974 | -9.875 | -12.444 | -11.311 | |
| Price To Earnings Diluted Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Price To Book Ratio | 8.841 | 5.583 | 4.023 | 5.856 | 4.105 | |
| Price To Sales Ratio | 0.000 | 0.000 | 466.175 | 0.000 | 284.114 | |
| Price To Free Cash Flow Ratio | -18.686 | -15.221 | -15.767 | -26.201 | -29.459 | |
| Price To Operating Cash Flow Ratio | -18.686 | -15.221 | -15.767 | -26.201 | -29.459 | |
| Debt To Assets Ratio | 0.013 | 0.011 | 0.007 | 0.007 | 0.007 | |
| Debt To Equity Ratio | 0.013 | 0.012 | 0.007 | 0.008 | 0.007 | |
| Debt To Capital Ratio | 0.013 | 0.011 | 0.007 | 0.008 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.061 | 1.080 | 1.049 | 1.047 | 1.023 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.008 | 0.000 | 0.024 | |
| Operating Cash Flow Ratio | -3.647 | -2.934 | -3.062 | -3.187 | -3.888 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -29.567 | 0.000 | -9.645 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -268.098 | 0.000 | 0.000 | -132.010 | -40,625.078 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -133.413 | -40,794.075 | |
| Short Term Operating Cash Flow Coverage Ratio | -174.951 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -35.162 | -31.616 | -35.480 | -29.376 | -19.066 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.099 | -8.736 | -9.830 | -11.505 | -8.913 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-9.6% |
| Ebit Margin | 0.0% | 0.0% | ▲1458.8% |
| Ebitda Margin | 0.0% | 0.0% | ▲1452.3% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1561.8% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲1458.5% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲1458.5% |
| Net Profit Margin | 0.0% | 0.0% | ▲1440.1% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲1440.4% |
| Current Ratio | 8.077 | ▼-0.468 | ▼-6.383 |
| Quick Ratio | 8.077 | ▼-0.468 | ▼-6.388 |
| Solvency Ratio | -5.113 | ▼-0.482 | ▲0.698 |
| Cash Ratio | 0.632 | ▲0.124 | ▼-5.487 |
| Price To Earnings Ratio | -12.147 | ▼-3.173 | ▼-1.197 |
| Price To Earnings Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Forward Price To Earnings Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Price To Earnings Diluted Ratio | -12.147 | ▼-3.173 | ▼-1.197 |
| Price To Earnings Diluted Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Price To Book Ratio | 8.841 | ▲3.258 | ▲3.159 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-150.058 |
| Price To Free Cash Flow Ratio | -18.686 | ▼-3.466 | ▲2.381 |
| Price To Operating Cash Flow Ratio | -18.686 | ▼-3.466 | ▲2.381 |
| Debt To Assets Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Debt To Equity Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Debt To Capital Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.061 | ▼-0.019 | ▲0.009 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.006 |
| Operating Cash Flow Ratio | -3.647 | ▼-0.713 | ▼-0.303 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲7.842 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | -268.098 | ▼-268.098 | ▲7936.939 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲8185.498 |
| Short Term Operating Cash Flow Coverage Ratio | -174.951 | ▼-174.951 | ▼-139.961 |
| Operating Cash Flow Coverage Ratio | -35.162 | ▼-3.545 | ▼-5.022 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.099 | ▼-3.364 | ▼-1.883 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $134.0M | $111.6M | $97.9M | $170.1M | $145.5M | |
| Enterprise value | $133.0M | $110.6M | $97.2M | $158.0M | $116.6M | |
| EV / Sales | 0.00x | 0.00x | 462.65x | 0.00x | 227.73x | |
| EV / Op. cash flow | -18.54x | -15.08x | -15.65x | -24.33x | -23.61x | |
| EV / Free cash flow | -18.54x | -15.08x | -15.65x | -24.33x | -23.61x | |
| EV / EBITDA | -12.10x | -8.74x | -9.83x | -11.51x | -8.91x | |
| Net debt / EBITDA | 0.10x | 0.08x | 0.07x | 0.88x | 2.21x | |
| Current ratio | 8.08x | 8.54x | 12.50x | 14.83x | 28.35x | |
| Income quality | 0.65x | 0.58x | 0.62x | 0.47x | 0.38x | |
| Graham net-net | $0 | $1 | $1 | $1 | $1 | |
| Tax burden | 99.1% | 98.9% | 98.8% | 98.7% | 98.6% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 99.9% | |
| Working capital | $13.9M | $18.9M | $23.3M | $28.2M | $34.7M | |
| Invested capital | $14.1M | $19.1M | $23.5M | $28.4M | $35.0M | |
| Return on assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | |
| Operating ROA | -62.1% | -58.7% | -39.4% | -41.6% | -57.5% | |
| Return on tangible assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | |
| Return on equity | -72.1% | -62.8% | -40.3% | -46.8% | -36.5% | |
| Return on invested capital | -82.7% | -72.3% | -46.8% | -48.8% | -37.5% | |
| Return on capital employed | -82.9% | -72.4% | -46.9% | -48.9% | -37.5% | |
| Earnings yield | -8.2% | -11.2% | -10.0% | -8.0% | -8.9% | |
| Free cash flow yield | -5.4% | -6.6% | -6.3% | -3.8% | -3.4% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 2995.7% | 0.0% | 1381.5% | |
| R&D / Sales | 0.0% | 0.0% | 2271.0% | 0.0% | 1208.9% | |
| Stock comp / Sales | 0.0% | 0.0% | 2105.7% | 0.0% | 1465.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 469d | 0d | 0d | |
| Days payables outstanding | 1673d | 0d | 467d | 0d | 129d | |
| Operating cycle | 0d | 0d | 469d | 0d | 0d | |
| Cash conversion cycle | -1673d | 0d | 2d | 0d | -129d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+20.1%EV / Sales n/aEV / EBITDA ▼-38.5%EV / Op. cash flow ▼-3.462Earnings yield ▲+0.031
Profitability
Return on equity ▼-0.093Return on assets ▼-0.098Return on invested capital ▼-0.103Return on capital employed ▼-0.105Operating ROA ▼-0.034Income quality ▲+0.073Tax burden ▲+0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.468Net debt / EBITDA ▲+0.013Working capital ▼-4942000.000Invested capital ▼-4978000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-7.9%EV / Sales ▼-100.0%EV / EBITDA ▼-35.7%EV / Op. cash flow ▲+5.071Earnings yield ▲+0.007
Profitability
Return on equity ▼-0.355Return on assets ▼-0.322Return on invested capital ▼-0.452Return on capital employed ▼-0.454Operating ROA ▼-0.046Income quality ▲+0.274Tax burden ▲+0.005
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+1543.982Operating cycle n/aCash conversion cycle ▼-1543.982Capex / Sales n/aR&D / Sales ▼-12.089
Balance-sheet strength
Current ratio ▼-20.272Net debt / EBITDA ▼-2.112Working capital ▼-20813449.000Invested capital ▼-20874404.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-21 Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 Composition of matter patent secures exclusive protection for Anixa''s breast cancer vaccine in Australia through 2040, expanding the Company''s growing global IP estate Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., Sept. 21, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa''s breast cancer vaccine technology, exclusively licensed from Cleveland Clinic.
- 2026-09-16 Anixa Biosciences Appoints UPenn''s Dr. Carmen Guerra to Cancer Business Advisory Board SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D.
- 2026-09-09 Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET.
- 2026-09-03 Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 Presentation to highlight Anixa''s clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO, has been invited to speak at the Nasdaq & LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, at Nasdaq''s San Francisco headquarters.
- 2026-08-24 Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Presentation to highlight Anixa''s clinical progress and collaborations with leading cancer research institutions— Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Aug. 24, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the 2026 Cantor Fitzgerald Global Healthcare Conference being held September 9 – 11, 2026, in New York City.
- 2026-08-18 Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Presentation to highlight Anixa''s clinical progress and collaborations with leading cancer research institutions—Moffitt Cancer Center and Cleveland Clinic SAN JOSE, Calif., Aug. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C.
- 2026-07-22 Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here''s What You Should Know Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 2026-07-22 New Strong Buy Stocks for July 22nd HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
- 2026-07-14 Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology Notice of Acceptance marks first Australian patent covering Anixa''s breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., July 14, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa''s breast cancer vaccine technology.
- 2026-07-06 Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer.